osteoarthritis
Conditions
Interventions
Participating general practices will be randomized to either: 1) prescribe duloxetine as third choice pain medication in combination with usual care
or 2) provide usual care only (no antidepressants for pain
medication).
Sponsors
Erasmus MC
ZonMw
Eligibility
Inclusion criteria
Inclusion criteria: 1) having hip or knee OA based on the clinical ACR criteria, and 2) having chronic pain (most days of the last three months) in hip or knee, and 3) either: (i) a contra-indication for NSAIDs; (ii) adverse reactions of NSAIDs; or (iii) insufficient benefit of NSAIDs.
Exclusion criteria
Exclusion criteria: 1) on waiting list for hip/knee replacement, and 2) use of antidepressants, 3) contra-indication of duloxetine (use of Monoamine Oxidase Inhibitors, having uncontrolled narrow-angle glaucoma, in combination with (other) central nervous system acting drugs, in combination with thioridazine, hypersensitivity to duloxetine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain at 3 months measured with the WOMAC pain subscale | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain at 1 year (WOMAC pain subscale), Disability (WOMAC function subscale) Adverse reactions Quality of life with the EQ-5D Compliance to treatment (Brief Medication Questionnaire) Patients’ satisfaction OARSI-OMERACT responder criteria Costs; including direct medical and patient costs (iMCQ) and productivity costs (iPCQ). | — |
Contacts
Public ContactD. Schiphof
Erasmus MC, kamer NA1906 Postbus 2040
Outcome results
None listed